Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Boston Scientific Co. stock logo
BSX
Boston Scientific
$99.29
-1.5%
$102.15
$66.80
$107.17
$146.86B0.776.05 million shs5.66 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$67.71
-2.5%
$82.65
$62.34
$141.99
$26.46B1.284.05 million shs3.13 million shs
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$491.84
-3.2%
$558.29
$364.17
$616.00
$175.18B1.431.53 million shs1.36 million shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Boston Scientific Co. stock logo
BSX
Boston Scientific
-1.53%-0.79%-0.18%+11.12%+46.81%
DexCom, Inc. stock logo
DXCM
DexCom
-3.69%-7.51%-21.34%-13.42%-50.19%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
-0.22%+3.27%-11.48%-5.04%+26.94%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Boston Scientific Co. stock logo
BSX
Boston Scientific
4.5936 of 5 stars
3.54.00.04.23.02.51.3
DexCom, Inc. stock logo
DXCM
DexCom
4.894 of 5 stars
4.43.00.04.73.52.51.9
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
4.6082 of 5 stars
3.33.00.04.03.62.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Boston Scientific Co. stock logo
BSX
Boston Scientific
3.00
Buy$108.919.69% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.89
Moderate Buy$99.8247.43% Upside
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
2.67
Moderate Buy$611.8624.40% Upside

Current Analyst Ratings Breakdown

Latest ISRG, DXCM, and BSX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/21/2025
DexCom, Inc. stock logo
DXCM
DexCom
Cfra Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
3/18/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$707.00 ➝ $600.00
3/17/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
3/17/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$666.00 ➝ $605.00
3/8/2025
DexCom, Inc. stock logo
DXCM
DexCom
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
3/4/2025
DexCom, Inc. stock logo
DXCM
DexCom
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$101.00 ➝ $104.00
3/3/2025
Boston Scientific Co. stock logo
BSX
Boston Scientific
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
2/18/2025
Boston Scientific Co. stock logo
BSX
Boston Scientific
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$130.00
2/14/2025
DexCom, Inc. stock logo
DXCM
DexCom
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$75.00 ➝ $82.00
2/14/2025
DexCom, Inc. stock logo
DXCM
DexCom
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$99.00 ➝ $103.00
2/10/2025
Boston Scientific Co. stock logo
BSX
Boston Scientific
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$111.00 ➝ $118.00
(Data available from 3/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Boston Scientific Co. stock logo
BSX
Boston Scientific
$16.75B8.77$3.44 per share28.86$14.91 per share6.66
DexCom, Inc. stock logo
DXCM
DexCom
$4.03B6.56$1.70 per share39.75$5.38 per share12.59
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$8.35B20.97$6.48 per share75.93$46.41 per share10.60
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Boston Scientific Co. stock logo
BSX
Boston Scientific
$1.85B$1.2579.4330.742.7911.07%17.80%9.85%4/23/2025 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$576.20M$1.4347.3527.522.3014.29%30.14%10.11%4/24/2025 (Estimated)
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$2.32B$6.4176.7364.465.8527.81%14.55%12.88%4/22/2025 (Estimated)

Latest ISRG, DXCM, and BSX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/24/2025N/A
DexCom, Inc. stock logo
DXCM
DexCom
$0.33N/AN/AN/A$1.02 billionN/A
4/23/2025N/A
Boston Scientific Co. stock logo
BSX
Boston Scientific
$0.67N/AN/AN/A$4.57 billionN/A
4/22/2025N/A
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$1.71N/AN/AN/A$2.19 billionN/A
2/13/2025Q4 2024
DexCom, Inc. stock logo
DXCM
DexCom
$0.50$0.45-$0.05$0.38$1.10 billionN/A
2/5/2025Q4 2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
$0.65$0.70+$0.05$0.38$4.42 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Boston Scientific Co. stock logo
BSX
Boston Scientific
N/AN/AN/AN/AN/A
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Boston Scientific Co. stock logo
BSX
Boston Scientific
0.41
1.08
1.02
DexCom, Inc. stock logo
DXCM
DexCom
0.59
1.47
1.28
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/A
4.07
3.22

Institutional Ownership

CompanyInstitutional Ownership
Boston Scientific Co. stock logo
BSX
Boston Scientific
89.07%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
83.64%

Insider Ownership

CompanyInsider Ownership
Boston Scientific Co. stock logo
BSX
Boston Scientific
0.50%
DexCom, Inc. stock logo
DXCM
DexCom
0.30%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
0.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Boston Scientific Co. stock logo
BSX
Boston Scientific
45,0001.48 billion1.47 billionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
7,600390.77 million389.60 millionOptionable
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
12,100356.18 million352.97 millionOptionable

Recent News About These Companies

Intuitive Surgical announces publication of two studies on Force Feedback tech

New MarketBeat Followers Over Time

Media Sentiment Over Time

Boston Scientific stock logo

Boston Scientific NYSE:BSX

$99.29 -1.51 (-1.50%)
Closing price 03:59 PM Eastern
Extended Trading
$99.40 +0.10 (+0.10%)
As of 04:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

DexCom stock logo

DexCom NASDAQ:DXCM

$67.71 -1.76 (-2.53%)
Closing price 03:59 PM Eastern
Extended Trading
$67.72 +0.02 (+0.02%)
As of 04:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Intuitive Surgical stock logo

Intuitive Surgical NASDAQ:ISRG

$491.84 -16.07 (-3.16%)
Closing price 03:59 PM Eastern
Extended Trading
$491.74 -0.09 (-0.02%)
As of 04:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.